Company Metrics

• 0 P/E
• 1.47 P/S
• 0.37 P/B
• -0.61 EPS
• -43.58% Cash ROIC
• 0.02 Cash Ratio
• 0 / 0% Dividend
• 182,435.00 Avg. Vol.
• 6.07M Shares
• 1.7M Market Cap.

Company Description

ULURU Inc., a pharmaceutical company, engages in the research, development, and commercialization of wound care and muco-adhesive film products in the United States and internationally. The company's products are based on patented Nanoflex and OraDisc drug delivery technologies. Its products include Altrazeal, a transforming powder dressing for the treatment of various wounds, such as partial thickness burns, donor sites, and abrasions, as well as surgical, acute, and chronic wounds; Aphthasol and Aptheal for the treatment of canker sores; OraDisc A for the treatment of oral conditions, which rely upon the use of medications formulated as gels and pastes that are applied to lesions in the mouth; OraDisc B for the treatment and management of oral pain; and Residerm A gel-Zindaclin for the treatment of acne. The company is based in Addison, Texas.
less

ULURU Inc., a pharmaceutical company, engages in the research, development, and commercialization of wound care and muco-adhesive film products in the United States and internationally. The company's products are based on patented Nanoflex and OraDisc drug delivery technologies. Its products include Altrazeal, a transforming powder dressing for the treatment of various wounds, such as partial thic...
more

News